On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
ThursdayDec 02, 2021 1:27 pm

QualityStocksNewsBreaks – Excellon Resources Inc.’s (NYSE American: EXN) (TSX: EXN) (FSE: E4X2) Platosa Marks 4th Quarter of >21,000 Tons Mined and Milled

Excellon Resources (NYSE American: EXN) (TSX: EXN) (FSE: E4X2) is a diversified metals producer with a precious metals growth pipeline that includes Mexico’s Platosa Mine, Kilgore, a high-quality gold development project in Idaho, as well as and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany boasting more than 750 years of mining history. The company recently released details of its robust second-quarter production numbers generated from its Durango, Mexico-based Platosa Mine. “Excellon saw silver production of 296,013 ounces, lead production of 1.9 million pounds and zinc production of 2.5 million pounds — in aggregate totaling…

Continue Reading

ThursdayDec 02, 2021 12:38 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX) has embarked on its most ambitious study yet, the HYPER-H21-4. The study is among several geared towards evaluating DehydraTECH(TM)-processed CBD for the potential treatment of hypertension and heart disease. The learnings from two studies, HYPER-H21-1 and HYPER-H21-2, whose results are already out, have led to the HYPER-H21-4 clinical study. Further, blood pressure findings from HYPER-H21-3 will be reportable by the end of January 2022 and will contribute to the HYPER-H21-4. The study protocols for HYPER-H21-4 are being readied for submission to the Independent Review Board (“IRB”), and approval is expected by January 2022. HYPER-H21-4, which…

Continue Reading

ThursdayDec 02, 2021 12:03 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Switzerland Ethics Committee Approval of Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has received approval from the Switzerland Ethics Committee (swissethics) — the first approval of its kind from a European ethics committee — for its study of Berubicin. Exclusive to CNS Pharmaceuticals, Berubicin is the first anthracycline that appears to cross the blood-brain barrier; the substance is being assessed in a global study designed to evaluate efficacy and safety in the treatment of recurrent glioblastoma multiforme (“GBM”). The adaptive, multicenter, open-label, randomized and controlled study…

Continue Reading

ThursdayDec 02, 2021 11:42 am

QualityStocksNewsBreaks – Simply Sonoma Enters Growing CBD-Infused Beverages Space

Simply Sonoma, a company committed to offering CBD products for the environmentally conscious consumer, is branching out into the beverage space with an alcohol-free, CBD wine product as well as a Pinot Noir/CBD sparkling product. A Facts and Factors report expects that the global CBD-infused beverages market will grow at a CAGR of approximately 27.5% between 2021 and 2026, driven by the rising authorization and certification for recreational cannabis in countries such as the United States and Canada (https://ibn.fm/rQu00). Furthermore, there is a growing movement away from smoking cannabis and adopting healthier edible options because of the increasing incidence of…

Continue Reading

ThursdayDec 02, 2021 11:31 am

QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Plans Opening of Two Additional Ketamine Wellness Centers

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that subsidiary Ketamine Wellness Centers (“KWC”) is planning to open new clinics in Salt Lake City, Utah, and Reno, Nevada; the clinics are slated to open by February 2022. The new clinics will bring the total of KWC locations to 12; the company currently has 10 ketamine infusion treatment clinics in eight different states and is positioned as the largest chain of wellness centers in the country. The Utah location will be one of KWC’s largest clinics, and the Reno clinic is strategically…

Continue Reading

ThursdayDec 02, 2021 10:28 am

QualityStocksNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Receives Initial Orders from Mexico, Spain

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is expanding internationally. The company’s Flora Beauty division received its first-ever orders for its Mind Naturals and Awe CBD skincare brands for the Spanish and Mexican markets; the company plans to ship the product this month. Flora Beauty’s Mind Naturals brand is designed with young consumers who are just starting a skincare routine while its the AWE brand targets consumers who value customized and personal experiences. The Mind Naturals line was recently named a top-12 finalist in a global pitch competition sponsored by Glosswire. The…

Continue Reading

ThursdayDec 02, 2021 10:01 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Green Light from FDA for Clinical Study in Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced its receipt of confirmation from the U.S. Food and Drug Administration (“FDA”) that its review of Tryp’s Investigational New Drug (“IND”) application is complete and that the company may proceed with its clinical study in fibromyalgia. The trial, which the company expects to initiate in 2022, is being conducted with Kevin Boehnke, Ph.D. from the University of Michigan and will evaluate Tryp’s oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. “The upcoming phase 2a study with…

Continue Reading

ThursdayDec 02, 2021 9:25 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in Future of Healthcare Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be presenting in the upcoming Stifel GMP second annual Future of Healthcare Conference. The conference, which is slated for Dec. 8, 2021, will include a presentation by Cybin CEO Doug Drysdale. According to the announcement, Drysdale’s presentation is scheduled to start at 3:30 p.m. ET. Following the presentation, interested viewers can view an archived version of the webcast on Cybin’s investor relations website. Cybin is working to create safe and effective therapeutics for patients to address a multitude of mental health issues. To view the…

Continue Reading

WednesdayDec 01, 2021 2:51 pm

QualityStocksNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reimagining Mental Health, Addiction Treatment

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, recently filed a patent application covering bioavailability-enhancing, nanoemulsion-empowered formulations. The move followed on the heels of a previous announcement that the company had filed a final patent application for MYCO-003, one of its lead drug candidates. Nanoemulsion is an advanced drug delivery system that offers enhanced stability, fast digestibility, controlled release and protection against degradation. “Specifically, Mydecine is targeting the enhanced bioavailability and controlled capabilities of the nanoemulsion technology. The system’s controlled-release capability, for example, will…

Continue Reading

WednesdayDec 01, 2021 2:43 pm

QualityStocksNewsBreaks – Friendable Inc. (FDBL) Providing Artists, Fans the Best that Music Offers

Friendable (OTC: FDBL), a mobile technology and marketing company, released Fan Pass in July 2020 as a platform for artists to share their work and fans to get a front-row seat to the action from the comfort of their home. Since then, the platform has grown considerably. “During the latter part of 2021, the company’s main focus has been to make the Fan Pass platform more visible and accessible. Now, the company is focusing on moving into 2022, offering artists and fans the best that music offers,” reads a recent article. “Artists who sign up with the Fan Pass platform…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered